Navigation Links
Intrexon and Rentokil Enter into Research and Development Agreement to Explore a New Generation of Highly-Effective, Sustainable Pest Controls
Date:9/13/2013

GERMANTOWN, Md., Sept. 13, 2013 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today that it has agreed to a joint research and development initiative with Rentokil Initial PLC that may lead to a new generation of highly-effective and sustainable pest control product and solution.

Under the agreement, Intrexon will apply its biology and science expertise to assist Rentokil in the development of specific pest control products.  The companies will also consider exploring additional areas of commercial product research and development.  Additional terms of the agreement were not disclosed.

Intrexon's Chief Operating Officer, Krish Krishnan, said Rentokil's long history of developing innovative pest control products is invaluable to the collaboration.

"Intrexon and Rentokil share a common DNA: an unwavering commitment to producing ground-breaking solutions," Krishnan said. "The same biotechnologies that have served and benefitted our collaborations in Health and Food will be equally valuable towards advancing our goals in Intrexon's emerging Environment group."

About Intrexon Corporation
Intrexon Corporation (NYSE: XON) is a biotechnology company focused on collaborating with companies in Health, Food, Energy, and the Environment to create biologically based products that improve the quality of life and health of the planet.  Through the company's proprietary UltraVector® platform, Intrexon provides its partners with commercial-scale design and development of complex biological systems.  The UltraVector® platform enables unprecedented control over the quality, function, and performance of living cells for a wide variety of applications.  Intrexon calls it Better DNA™ and invites you to discover more at www.dna.com.

Trademarks
Intrexon, UltraVector and Better DNA are trademarks of Intrexon and/or its affiliates.  Other names may be trademarks of their respective owners.

Safe Harbor Statement
Some of the statements made in this press release are forward-looking statements.  These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business.  Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

For more information contact:


Intrexon Corporation Contact:


Marie L. Rossi, Ph.D.

Manager, Technical Communications

Tel: +1 301-556-9944

mrossi@intrexon.com



 


'/>"/>
SOURCE Intrexon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Synthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases
2. Synthetic Biologics Reiterates that the Infectious Disease Collaboration with Intrexon Remains in Effect
3. Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives
4. Intrexon Organizes Around New Synthetic Biology Markets
5. Intrexon Announces Filing of Registration Statement For Proposed Initial Public Offering
6. Intrexon Prices Initial Public Offering
7. Intrexon Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option by Underwriters
8. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
9. Pittsburgh Based ParentPlus Enters Collaboration with Vitrolife
10. Two Top Biological Imaging Centers Offer Powerful Free Online Tool to Researchers, Educators, and Public
11. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... Italy , April 29, 2016 ... 5.11, the latest update to its industry-leading treatment planning ... shown that Monaco version 5.11 ... can now attain calculation speeds up to four times ... . With the industry,s gold standard ...
(Date:4/28/2016)... NEW YORK , April 28, 2016 /PRNewswire/ ... biotechnology acceleration company reports the Company,s CEO  was ... capital titled Accelerators Enter When VCs Fear To ... Life Science Leader magazine is an ... work for everything from emerging biotechs to Big ...
(Date:4/28/2016)... ... April 28, 2016 , ... Next week on ... on its first-in-class technologies for tissue stem cell counting and expansion to gene-editing ... to Reprogramming & CRISPR-based Genome Engineering in Burlington, Massachusetts. , The attention of ...
(Date:4/28/2016)... ... 2016 , ... Morris Midwest ( http://www.morrismidwest.com ), a division ... its Maple Grove, Minnesota technical center, May 11-12. The event will feature ... 20 leading suppliers of tooling, accessories, software and other related technology will participate ...
Breaking Biology Technology:
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/22/2016)... March 22, 2016 ... Sensors Market for Consumer Industry by Type (Image, ... Application (Communication & IT, Entertainment, Home Appliances, ... Forecast to 2022", published by MarketsandMarkets, the ... to reach USD 26.76 Billion by 2022, ...
(Date:3/15/2016)... , March 15, 2016 --> ... published by Transparency Market Research "Digital Door Lock Systems Market ... 2015 - 2023," the global digital door lock systems market ... in 2014 and is forecast to grow at a CAGR ... micro, small and medium enterprises (MSMEs) across the world and ...
Breaking Biology News(10 mins):